DRUG-CLASS OVERVIEW:@0.982174:0.513429:0.982174:0.311367:0.954164:0.311367:0.954164:0.513429:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.233372:0.041064:0.000000:0.000000:0.019473
205:@0.945393:0.038601:0.984904:0.038601:0.984904:0.019004:0.945393:0.019004:0.013170:0.013170:0.013170
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
REFERENCES:@0.084848:0.079499:0.195685:0.079499:0.195685:0.063465:0.084848:0.063465:0.011161:0.010006:0.009236:0.010006:0.011161:0.010006:0.014239:0.015009:0.010006:0.010006
1. :@0.084848:0.093312:0.103800:0.093312:0.103800:0.079307:0.084848:0.079307:0.009476:0.004738:0.004738
  English MW.  Principles of  chemotherapy. :@0.131885:0.093312:0.480523:0.093312:0.480523:0.079307:0.131885:0.079307:0.004738:-0.004738:0.009168:0.010434:0.011511:0.003421:0.003421:0.006636:0.010434:0.007663:0.015719:0.015149:0.004738:0.004738:0.002911:0.010126:0.005148:0.003421:0.010434:0.011067:0.003421:0.011665:0.003421:0.011118:0.006636:0.007663:0.011203:0.005371:0.004738:0.002909:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
Paediatrics and Child  Health. :@0.131885:0.107447:0.401614:0.107447:0.401614:0.093442:0.131885:0.093442:0.010126:0.011682:0.011118:0.011716:0.003421:0.011682:0.005798:0.005148:0.003421:0.011067:0.006636:0.012520:0.011682:0.010434:0.011716:0.012520:0.013906:0.010434:0.003421:0.003421:0.011716:0.004738:0.007793:0.011682:0.011118:0.011682:0.003421:0.005798:0.010434:0.004738:0.004738
2010;20: :@0.409397:0.107447:0.480465:0.107447:0.480465:0.093442:0.409397:0.093442:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.004738
123-128. :@0.131885:0.121581:0.203895:0.121581:0.203895:0.107576:0.131885:0.107576:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738:0.004738
2. :@0.084848:0.135716:0.103800:0.135716:0.103800:0.121711:0.084848:0.121711:0.009476:0.004738:0.004738
  Caley A, Jones R. The principles of cancer :@0.131885:0.135716:0.480515:0.135716:0.480515:0.121711:0.131885:0.121711:0.004738:-0.004738:0.013906:0.011682:0.003421:0.011118:0.009168:0.004362:0.012657:0.004738:0.004362:0.008244:0.011203:0.010434:0.011118:0.006636:0.004362:0.010382:0.004738:0.004362:0.007286:0.010434:0.011118:0.004353:0.011665:0.005148:0.003421:0.010434:0.011067:0.003421:0.011665:0.003421:0.011118:0.006636:0.004362:0.011203:0.005371:0.004362:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
treatment by chemotherapy. :@0.131885:0.149851:0.402984:0.149851:0.402984:0.135845:0.131885:0.135845:0.005798:0.005075:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.016523:0.011665:0.009168:0.016523:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
Surgery :@0.414757:0.149851:0.480506:0.149851:0.480506:0.135845:0.414757:0.135845:0.008518:0.010399:0.005148:0.011511:0.011118:0.005148:0.009168:0.004738
(Oxford).:@0.131885:0.163985:0.205759:0.163985:0.205759:0.149980:0.131885:0.149980:0.006312:0.014864:0.008210:0.005371:0.011203:0.005148:0.011716:0.006312:0.004738
 2012;30:186-190.:@0.205759:0.163985:0.344099:0.163985:0.344099:0.149980:0.205759:0.149980:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
3. :@0.084848:0.178120:0.103800:0.178120:0.103800:0.164115:0.084848:0.164115:0.009476:0.004738:0.004738
  Katzung  BG, Masters SB, Trevor AJ. :@0.131885:0.178120:0.430478:0.178120:0.430478:0.164115:0.131885:0.164115:0.004738:-0.004738:0.010109:0.011682:0.005798:0.007269:0.010399:0.010434:0.011511:0.004738:0.002637:0.009818:0.014915:0.004738:0.007389:0.015719:0.011682:0.006636:0.005798:0.011118:0.005148:0.006636:0.007389:0.008518:0.009818:0.004738:0.007389:0.006773:0.005078:0.011118:0.009476:0.011203:0.005148:0.007389:0.012657:0.008244:0.004738:0.004738
Basic :@0.433129:0.178120:0.480491:0.178120:0.480491:0.164115:0.433129:0.164115:0.009818:0.011682:0.006636:0.003421:0.011067:0.004738
and Clinical Pharmacology.:@0.131885:0.192255:0.368232:0.192255:0.368232:0.178249:0.131885:0.178249:0.011682:0.010434:0.011716:0.007150:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.007165:0.010126:0.010434:0.011682:0.005148:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
 McGraw-Hill :@0.368216:0.192255:0.480472:0.192255:0.480472:0.178249:0.368216:0.178249:0.007150:0.015719:0.011067:0.014915:0.005148:0.011682:0.014214:0.005679:0.011682:0.003421:0.003421:0.003421:0.004738
Companies, Inc. (Published online  2009  :@0.131885:0.206389:0.480510:0.206389:0.480510:0.192384:0.131885:0.192384:0.013906:0.011203:0.016044:0.011665:0.011682:0.010434:0.003421:0.011118:0.006636:0.004738:0.009938:0.003866:0.010434:0.011067:0.004738:0.009938:0.006312:0.010126:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.009938:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.005189:0.009476:0.009476:0.009476:0.009476:0.000000:0.004738
pg 1232).:@0.131885:0.220524:0.208752:0.220524:0.208752:0.206519:0.131885:0.206519:0.011665:0.011511:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
4. :@0.084848:0.234659:0.103800:0.234659:0.103800:0.220653:0.084848:0.220653:0.009476:0.004738:0.004738
  Katzung  BG, Masters SB, Trevor AJ. :@0.131885:0.234659:0.430478:0.234659:0.430478:0.220653:0.131885:0.220653:0.004738:-0.004738:0.010109:0.011682:0.005798:0.007269:0.010399:0.010434:0.011511:0.004738:0.002637:0.009818:0.014915:0.004738:0.007389:0.015719:0.011682:0.006636:0.005798:0.011118:0.005148:0.006636:0.007389:0.008518:0.009818:0.004738:0.007389:0.006773:0.005078:0.011118:0.009476:0.011203:0.005148:0.007389:0.012657:0.008244:0.004738:0.004738
Basic :@0.433129:0.234659:0.480491:0.234659:0.480491:0.220653:0.433129:0.220653:0.009818:0.011682:0.006636:0.003421:0.011067:0.004738
and Clinical Pharmacology:@0.131885:0.248652:0.358419:0.248652:0.358419:0.234647:0.131885:0.234647:0.011682:0.010434:0.011716:0.004618:0.013906:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004630:0.010126:0.010434:0.011682:0.005140:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168
. 11th Ed. 2009 :@0.358419:0.248652:0.480458:0.248652:0.480458:0.234647:0.358419:0.234647:0.004738:0.004618:0.009476:0.009476:0.005798:0.010434:0.004618:0.009168:0.011716:0.004738:0.004618:0.009476:0.009476:0.009476:0.009476:0.004738
GIFVol 46 KB. (The  McGraw-Hill Compa-:@0.131885:0.262646:0.475762:0.262646:0.475762:0.248640:0.131885:0.248640:0.014915:0.003866:0.008296:0.010281:0.011203:0.003421:0.008518:0.009476:0.009476:0.008518:0.010109:0.009818:0.004738:0.008518:0.006312:0.007286:0.010434:0.011118:0.004738:0.003772:0.015719:0.011067:0.014915:0.005148:0.011682:0.014214:0.005679:0.011682:0.003421:0.003421:0.003421:0.008518:0.013906:0.011203:0.016044:0.011665:0.011682:0.005679
nies, Inc. 2009).:@0.131885:0.276639:0.256764:0.276639:0.256764:0.262634:0.131885:0.262634:0.010434:0.003421:0.011118:0.006636:0.004738:0.004738:0.003866:0.010434:0.011067:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
5. :@0.084848:0.290633:0.103800:0.290633:0.103800:0.276627:0.084848:0.276627:0.009476:0.004738:0.004738
  Huitema  AD,:@0.131885:0.290633:0.240029:0.290633:0.240029:0.276627:0.131885:0.276627:0.004738:-0.004738:0.011682:0.010399:0.003421:0.005798:0.011118:0.016044:0.011682:0.004738:0.003140:0.012657:0.012726:0.004738
 et  al.:@0.240029:0.290633:0.292545:0.290633:0.292545:0.276627:0.240029:0.276627:0.007885:0.011118:0.005798:0.004738:0.003135:0.011682:0.003421:0.004738
  The  clinical pharma-:@0.292545:0.290633:0.475758:0.290633:0.475758:0.276627:0.292545:0.276627:0.004738:0.003139:0.007286:0.010434:0.011118:0.004738:0.003134:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.007885:0.011665:0.010434:0.011682:0.005624:0.016044:0.011682:0.005679
cology  of  alkylating agents  in high-dose :@0.131885:0.304626:0.480506:0.304626:0.480506:0.290621:0.131885:0.290621:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.002742:0.011203:0.005371:0.004738:0.002742:0.011682:0.003421:0.008586:0.009168:0.003421:0.011682:0.005798:0.003421:0.010434:0.011511:0.007492:0.011682:0.011511:0.011118:0.010434:0.005798:0.006636:0.004738:0.002744:0.003421:0.010434:0.007492:0.010434:0.003421:0.011511:0.010434:0.005679:0.011716:0.011203:0.006636:0.011118:0.004738
chemotherapy. :@0.131885:0.318620:0.266240:0.318620:0.266240:0.304614:0.131885:0.304614:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.004738:0.004738
Anti-Cancer Drugs. :@0.267865:0.318620:0.431470:0.318620:0.431470:0.304614:0.267865:0.304614:0.012657:0.010434:0.005798:0.003421:0.005679:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.006365:0.012726:0.005148:0.010399:0.011511:0.006636:0.004738:0.004738
2000; :@0.433112:0.318620:0.480491:0.318620:0.480491:0.304614:0.433112:0.304614:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738
11:515-533.:@0.131885:0.332613:0.222846:0.332613:0.222846:0.318608:0.131885:0.318608:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
6. :@0.084848:0.346607:0.103800:0.346607:0.103800:0.332601:0.084848:0.332601:0.009476:0.004738:0.004738
  Sanderson  BJS, Shield AJ. Mutagenic :@0.131885:0.346607:0.480513:0.346607:0.480513:0.332601:0.131885:0.332601:0.004738:-0.004738:0.008518:0.011682:0.010434:0.011716:0.011118:0.005148:0.006636:0.011203:0.010434:0.004738:0.010321:0.009818:0.008244:0.008518:0.004738:0.015069:0.008518:0.010434:0.003421:0.011118:0.003421:0.011716:0.015069:0.012657:0.008244:0.004738:0.015069:0.015719:0.010399:0.005798:0.011682:0.011511:0.011118:0.010434:0.003421:0.011067:0.004738
damage  to  mammalian cells by  thera-:@0.131885:0.360600:0.475751:0.360600:0.475751:0.346595:0.131885:0.346595:0.011716:0.011682:0.016044:0.011682:0.011511:0.011118:0.004738:0.004522:0.005798:0.011203:0.004738:0.004516:0.016044:0.011682:0.016044:0.016044:0.011682:0.003421:0.003421:0.011682:0.010434:0.009271:0.011067:0.011118:0.003421:0.003421:0.006636:0.009271:0.011665:0.009168:0.004738:0.004524:0.005798:0.010434:0.011118:0.005148:0.011667:0.005679
peutic alkylating agents. :@0.131885:0.374594:0.355012:0.374594:0.355012:0.360588:0.131885:0.360588:0.011665:0.011118:0.010399:0.005798:0.003421:0.011067:0.011939:0.011682:0.003421:0.008586:0.009168:0.003421:0.011682:0.005798:0.003421:0.010434:0.011511:0.011939:0.011682:0.011511:0.011118:0.010434:0.005798:0.006636:0.004738:0.004738
Mutation  Re-:@0.362196:0.374594:0.475758:0.374594:0.475758:0.360588:0.362196:0.360588:0.015719:0.010399:0.005798:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.007191:0.010382:0.011118:0.005679
search/Fundamental:@0.131885:0.388587:0.306470:0.388587:0.306470:0.374582:0.131885:0.374582:0.006636:0.011118:0.011682:0.005148:0.011067:0.010434:0.007475:0.008296:0.010399:0.010434:0.011716:0.011682:0.016044:0.011118:0.010434:0.005798:0.011682:0.003421
and:@0.332605:0.388587:0.366437:0.388587:0.366437:0.374582:0.332605:0.374582:0.011682:0.010434:0.011716
Molecular:@0.392581:0.388587:0.475760:0.388587:0.475760:0.374582:0.392581:0.374582:0.015719:0.011203:0.003421:0.011118:0.011067:0.010399:0.003421:0.011682:0.005148
Mechanisms of  Mutagenesis.:@0.131885:0.402581:0.386916:0.402581:0.386916:0.388575:0.131885:0.388575:0.015719:0.011118:0.011067:0.010434:0.011682:0.010434:0.003421:0.006636:0.016044:0.006636:0.013034:0.011203:0.005371:0.004738:0.008284:0.015719:0.010399:0.005798:0.011682:0.011511:0.011118:0.010434:0.011118:0.006636:0.003421:0.006636:0.004738
  1996;355: :@0.386916:0.402581:0.480486:0.402581:0.480486:0.388575:0.386916:0.388575:0.004738:0.008287:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.004738
41-57.:@0.131885:0.416574:0.180205:0.416574:0.180205:0.402569:0.131885:0.402569:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
7. :@0.084848:0.430568:0.103800:0.430568:0.103800:0.416562:0.084848:0.416562:0.009476:0.004738:0.004738
  ThioTEPA. 8 February 2013 Ed. (DrugBank, :@0.131885:0.430568:0.480488:0.430568:0.480488:0.416562:0.131885:0.416562:0.004738:-0.004738:0.007286:0.010434:0.003421:0.011203:0.007286:0.009168:0.008845:0.012657:0.004738:0.006365:0.009476:0.006370:0.008296:0.011118:0.011665:0.005148:0.010399:0.011682:0.005148:0.009168:0.006363:0.009476:0.009476:0.009476:0.009476:0.006380:0.009168:0.011716:0.004738:0.006368:0.006312:0.012726:0.005148:0.010399:0.011511:0.009818:0.011682:0.010434:0.008586:0.004738:0.004738
published online 2013).:@0.131885:0.444561:0.320820:0.444561:0.320820:0.430556:0.131885:0.430556:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
8. :@0.084848:0.458555:0.103800:0.458555:0.103800:0.444550:0.084848:0.444550:0.009476:0.004738:0.004738
  Sunil VR,:@0.131885:0.458555:0.201964:0.458555:0.201964:0.444550:0.131885:0.444550:0.004738:-0.004738:0.008518:0.010399:0.010434:0.003421:0.003421:0.006758:0.012007:0.010382:0.004738
 et al.:@0.201964:0.458555:0.252233:0.458555:0.252233:0.444550:0.201964:0.444550:0.006756:0.011118:0.005798:0.006756:0.011682:0.003421:0.004738
 Functional and inflamma-:@0.252233:0.458555:0.475760:0.458555:0.475760:0.444550:0.252233:0.444550:0.006755:0.008296:0.010399:0.010434:0.011067:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.006748:0.011682:0.010434:0.011716:0.006756:0.003421:0.010434:0.004148:0.004148:0.011682:0.016044:0.016044:0.011682:0.005679
tory alterations in the lung following expo-:@0.131885:0.472548:0.475777:0.472548:0.475777:0.458543:0.131885:0.458543:0.005798:0.011203:0.005148:0.009168:0.004524:0.011682:0.003421:0.005798:0.011118:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.004533:0.003421:0.010434:0.004533:0.005798:0.010434:0.011118:0.004533:0.003421:0.010399:0.010434:0.011511:0.004533:0.005371:0.011203:0.003421:0.003421:0.011203:0.014214:0.003421:0.010434:0.011511:0.004533:0.011118:0.008210:0.011665:0.011203:0.005679
sure of rats to nitrogen mustard. :@0.131885:0.486542:0.402141:0.486542:0.402141:0.472537:0.131885:0.472537:0.006636:0.010399:0.005080:0.011118:0.005679:0.011203:0.005371:0.005679:0.005148:0.011682:0.005798:0.006636:0.005679:0.005798:0.011203:0.005679:0.010434:0.003421:0.005798:0.005078:0.011203:0.011511:0.011118:0.010434:0.005670:0.016044:0.010399:0.006636:0.005798:0.011682:0.005046:0.011716:0.004738:0.004738
Toxicolo-:@0.403082:0.486542:0.475775:0.486542:0.475775:0.472537:0.403082:0.472537:0.007286:0.011203:0.008210:0.003421:0.011067:0.011203:0.003421:0.011203:0.005679
gy and Applied Pharmacology.:@0.131885:0.500535:0.394831:0.500535:0.394831:0.486530:0.131885:0.486530:0.011511:0.009168:0.005114:0.011682:0.010434:0.011716:0.005114:0.012657:0.011665:0.011665:0.003421:0.003421:0.011118:0.011716:0.005114:0.010126:0.010434:0.011682:0.005148:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
 2011;250: :@0.394814:0.500535:0.480472:0.500535:0.480472:0.486530:0.394814:0.486530:0.005114:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.004738
10-18.:@0.131885:0.514529:0.180205:0.514529:0.180205:0.500524:0.131885:0.500524:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
9. :@0.084848:0.528522:0.103800:0.528522:0.103800:0.514517:0.084848:0.514517:0.009476:0.004738:0.004738
  Sharma M, Vijayaraghavan R, Gautam A. :@0.131885:0.528522:0.480501:0.528522:0.480501:0.514517:0.131885:0.514517:0.004738:-0.004738:0.008518:0.010434:0.011682:0.005620:0.016044:0.011682:0.004567:0.015719:0.004738:0.004567:0.012094:0.003421:0.003472:0.011682:0.009168:0.011682:0.005148:0.011682:0.011511:0.010434:0.011682:0.009476:0.011682:0.010434:0.004567:0.010382:0.004738:0.004567:0.014915:0.011682:0.010399:0.005798:0.011682:0.016044:0.004567:0.012657:0.004738:0.004738
DRDE-07 and its analogues  as promising :@0.131885:0.542516:0.480496:0.542516:0.480496:0.528511:0.131885:0.528511:0.012726:0.010382:0.012726:0.009168:0.005679:0.009476:0.009476:0.007748:0.011682:0.010434:0.011716:0.007748:0.003421:0.005798:0.006636:0.007748:0.011682:0.010434:0.011682:0.003421:0.011203:0.011511:0.010399:0.011118:0.006636:0.004738:0.003002:0.011682:0.006636:0.007748:0.011665:0.005078:0.011203:0.016044:0.003421:0.006636:0.003421:0.010434:0.011511:0.004738
cytoprotectants to nitrogen mustard (HN-:@0.131885:0.556509:0.475760:0.556509:0.475760:0.542504:0.131885:0.542504:0.011067:0.009168:0.005798:0.011203:0.011665:0.005077:0.011203:0.005798:0.011118:0.011067:0.005798:0.011682:0.010434:0.005798:0.006636:0.005172:0.005798:0.011203:0.005183:0.010434:0.003421:0.005798:0.005077:0.011203:0.011511:0.011118:0.010434:0.005174:0.016044:0.010399:0.006636:0.005798:0.011682:0.005046:0.011716:0.005183:0.006312:0.011682:0.012657:0.005679
2) – an alkylating anticancer and chemi-:@0.131885:0.570503:0.475753:0.570503:0.475753:0.556498:0.131885:0.556498:0.009476:0.006312:0.005815:0.008552:0.005807:0.011682:0.010434:0.005807:0.011682:0.003421:0.008586:0.009168:0.003421:0.011682:0.005798:0.003421:0.010434:0.011511:0.005807:0.011682:0.010434:0.005798:0.003421:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.005800:0.011682:0.010434:0.011716:0.005807:0.011067:0.010434:0.011118:0.016044:0.003421:0.005679
cal warfare agent. :@0.131885:0.584496:0.308878:0.584496:0.308878:0.570491:0.131885:0.570491:0.011067:0.011682:0.003421:0.012845:0.014214:0.011682:0.005966:0.005371:0.011682:0.005080:0.011118:0.012845:0.011682:0.011511:0.011118:0.010434:0.005798:0.004738:0.004738
Toxicology  Letters:@0.316989:0.584496:0.471039:0.584496:0.471039:0.570491:0.316989:0.570491:0.007286:0.011203:0.008210:0.003421:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738:0.008099:0.007902:0.011118:0.005798:0.005798:0.011118:0.005148:0.006636
. :@0.471031:0.584496:0.480506:0.584496:0.480506:0.570491:0.471031:0.570491:0.004738:0.004738
2009;188:243-250.:@0.131902:0.598490:0.274980:0.598490:0.274980:0.584485:0.131902:0.584485:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
10. :@0.084865:0.612483:0.113293:0.612483:0.113293:0.598478:0.084865:0.598478:0.009476:0.009476:0.004738:0.004738
  Baradaran-Rafii  A,  Eslani  M,  Tseng  SCG. :@0.131902:0.612483:0.480513:0.612483:0.480513:0.598478:0.131902:0.598478:0.004738:-0.004738:0.009818:0.011682:0.005148:0.011682:0.011716:0.011682:0.005148:0.011682:0.010434:0.005679:0.010382:0.011682:0.004165:0.004165:0.003421:0.004738:0.004086:0.012657:0.004738:0.004738:0.004076:0.009168:0.006636:0.003421:0.011682:0.010434:0.003421:0.004738:0.004095:0.015719:0.004738:0.004738:0.004078:0.006891:0.006636:0.011118:0.010434:0.011511:0.004738:0.004079:0.008518:0.013906:0.014915:0.004738:0.004738
Sulfur mustard-induced ocular surface dis-:@0.131902:0.626477:0.475765:0.626477:0.475765:0.612472:0.131902:0.612472:0.008518:0.010399:0.003421:0.005371:0.010399:0.005148:0.003780:0.016044:0.010399:0.006636:0.005798:0.011682:0.005046:0.011716:0.005679:0.003421:0.010434:0.011716:0.010399:0.011067:0.011118:0.011716:0.003780:0.011203:0.011067:0.010399:0.003421:0.011682:0.005148:0.003780:0.006636:0.010399:0.005966:0.005371:0.011682:0.011067:0.011118:0.003780:0.011716:0.003421:0.006636:0.005679
orders. :@0.131902:0.640471:0.192241:0.640471:0.192241:0.626465:0.131902:0.626465:0.011203:0.005041:0.011716:0.011118:0.005148:0.006636:0.004738:0.004738
The  Ocular  Surface.:@0.206991:0.640471:0.399421:0.640471:0.399421:0.626465:0.206991:0.626465:0.007286:0.010434:0.011118:0.004738:0.014744:0.014864:0.011067:0.010399:0.003421:0.011682:0.005148:0.004738:0.014751:0.008518:0.010399:0.005148:0.005371:0.011682:0.011067:0.011118:0.004738
  2011;9: :@0.399415:0.640471:0.480498:0.640471:0.480498:0.626465:0.399415:0.626465:0.004738:0.014753:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.004738:0.004738
163-178.:@0.131902:0.654464:0.199174:0.654464:0.199174:0.640459:0.131902:0.640459:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
11. :@0.084865:0.668458:0.113293:0.668458:0.113293:0.654452:0.084865:0.654452:0.009476:0.009476:0.004738:0.004738
  Ghotbi L, Hassan Z. The immunostatus of :@0.131902:0.668458:0.480518:0.668458:0.480518:0.654452:0.131902:0.654452:0.004738:-0.004738:0.014915:0.010434:0.011203:0.005798:0.011665:0.003421:0.007030:0.007902:0.004738:0.007030:0.011682:0.011682:0.006636:0.006636:0.011682:0.010434:0.007042:0.008210:0.004738:0.007030:0.007286:0.010434:0.011118:0.007030:0.003421:0.016044:0.016044:0.010399:0.010434:0.011203:0.006636:0.005798:0.011682:0.005798:0.010399:0.006636:0.007030:0.011203:0.005371:0.004738
natural killer cells in people exposed to :@0.131902:0.682451:0.480523:0.682451:0.480523:0.668446:0.131902:0.668446:0.010434:0.011682:0.005798:0.010399:0.005148:0.011682:0.003421:0.008638:0.008586:0.003421:0.003421:0.003421:0.011118:0.005148:0.008638:0.011067:0.011118:0.003421:0.003421:0.006636:0.008638:0.003421:0.010434:0.008638:0.011665:0.011118:0.011203:0.011665:0.003421:0.011118:0.008638:0.011118:0.008210:0.011665:0.011203:0.006636:0.011118:0.011716:0.008638:0.005798:0.011203:0.004738
sulfur mustard. :@0.131902:0.696445:0.254548:0.696445:0.254548:0.682439:0.131902:0.682439:0.006636:0.010399:0.003421:0.005371:0.010399:0.005148:0.004471:0.016044:0.010399:0.006636:0.005798:0.011682:0.005046:0.011716:0.004738:0.004738
International Immunophar-:@0.254284:0.696445:0.475786:0.696445:0.475786:0.682439:0.254284:0.682439:0.003866:0.010434:0.005798:0.011118:0.005148:0.010434:0.011682:0.005798:0.003421:0.011203:0.010434:0.011682:0.003421:0.004464:0.003866:0.016044:0.016044:0.010399:0.010434:0.011203:0.011665:0.010434:0.011682:0.005148:0.005679
macology.:@0.131902:0.710438:0.221940:0.710438:0.221940:0.696433:0.131902:0.696433:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.004738
 2002;2:981-985.:@0.221940:0.710438:0.350804:0.710438:0.350804:0.696433:0.221940:0.696433:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.004738:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
12. :@0.084865:0.724432:0.113293:0.724432:0.113293:0.710426:0.084865:0.710426:0.009476:0.009476:0.004738:0.004738
  Chemocare.com.  in :@0.131902:0.724432:0.312302:0.724432:0.312302:0.710426:0.131902:0.710426:0.004738:-0.004738:0.013906:0.010434:0.011118:0.016044:0.011203:0.011067:0.011682:0.005071:0.011118:0.004738:0.011067:0.011203:0.016044:0.004738:0.004738:0.007637:0.003421:0.010434:0.004738
Nitrogen  mustard. :@0.319948:0.724432:0.480510:0.724432:0.480510:0.710426:0.319948:0.710426:0.012657:0.003421:0.005798:0.005148:0.011203:0.011511:0.011118:0.010434:0.004738:0.007632:0.016044:0.010399:0.006636:0.005798:0.011682:0.005148:0.011716:0.004738:0.004738
Vol. 2013 (4th Angel Mentoring Program, :@0.131902:0.738425:0.480547:0.738425:0.480547:0.724420:0.131902:0.724420:0.010281:0.011203:0.003421:0.004738:0.006979:0.009476:0.009476:0.009476:0.009476:0.006989:0.006312:0.009476:0.005798:0.010434:0.006979:0.012657:0.010434:0.011511:0.011118:0.003421:0.006979:0.015719:0.011118:0.010434:0.005798:0.011203:0.005148:0.003421:0.010434:0.011511:0.006958:0.010126:0.005078:0.011203:0.011511:0.005148:0.011682:0.016044:0.004738:0.004738
published online 2002-2013).:@0.131902:0.752419:0.364419:0.752419:0.364419:0.738413:0.131902:0.738413:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.009476:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
13. :@0.084865:0.766412:0.113293:0.766412:0.113293:0.752407:0.084865:0.752407:0.009476:0.009476:0.004738:0.004738
  Editor Snyman, JR. Cytostatics. :@0.131902:0.766412:0.385953:0.766412:0.385953:0.752407:0.131902:0.752407:0.004738:-0.004738:0.009168:0.011716:0.003421:0.005798:0.011203:0.005148:0.004208:0.008518:0.010434:0.009168:0.016044:0.011682:0.010434:0.004738:0.004208:0.008244:0.010382:0.004738:0.004208:0.013906:0.009168:0.005798:0.011203:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.006636:0.004738:0.004738
Monthly In-:@0.385423:0.766412:0.475786:0.766412:0.475786:0.752407:0.385423:0.752407:0.015719:0.011203:0.010434:0.005798:0.010434:0.003421:0.009168:0.004208:0.003866:0.010434:0.005679
dex of  Medical Specialities.:@0.131902:0.780547:0.371184:0.780547:0.371184:0.766542:0.131902:0.766542:0.011716:0.011118:0.008210:0.009168:0.011203:0.005371:0.004738:0.004421:0.015719:0.011118:0.011716:0.003421:0.011067:0.011682:0.003421:0.009168:0.008518:0.011665:0.011118:0.011067:0.003421:0.011682:0.003421:0.003421:0.005798:0.003421:0.011118:0.006636:0.004738
 57, 364-370 :@0.371192:0.780547:0.480489:0.780547:0.480489:0.766542:0.371192:0.766542:0.009168:0.009476:0.009476:0.004738:0.009168:0.009476:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
(2017).:@0.131902:0.794681:0.187167:0.794681:0.187167:0.780676:0.131902:0.780676:0.006312:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
14. :@0.084865:0.808816:0.113293:0.808816:0.113293:0.794811:0.084865:0.794811:0.009476:0.009476:0.004738:0.004738
  GlaxoSmithKline.  LEUKERAN . 1-6. (Pub-:@0.131902:0.808816:0.475760:0.808691:0.475760:0.794686:0.131902:0.794811:0.004738:-0.004738:0.014915:0.003421:0.011682:0.008210:0.011203:0.008518:0.016044:0.003421:0.005798:0.010434:0.010109:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.007931:0.007902:0.009168:0.011203:0.010109:0.009168:0.010382:0.012657:0.012657:0.007420:0.004738:0.012674:0.009476:0.005679:0.009476:0.004738:0.012674:0.006312:0.010126:0.010399:0.011665:-0.171443
®:@0.364675:0.803697:0.372124:0.803697:0.372124:0.795532:0.364675:0.795532:0.007449
lished online, 2003).:@0.131877:0.822826:0.291820:0.822826:0.291820:0.808821:0.131877:0.808821:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
15. :@0.084840:0.836961:0.113267:0.836961:0.113267:0.822955:0.084840:0.822955:0.009476:0.009476:0.004738:0.004738
  Hoechst Marion Roussel Limited. Endoxan. :@0.131877:0.836961:0.480493:0.836961:0.480493:0.822955:0.131877:0.822955:0.004738:-0.004738:0.011682:0.011203:0.011118:0.011067:0.010434:0.006636:0.005798:0.004196:0.015719:0.011682:0.005148:0.003421:0.011203:0.010434:0.004194:0.010382:0.011203:0.010399:0.006636:0.006636:0.011118:0.003421:0.004208:0.007902:0.003421:0.016044:0.003421:0.005798:0.011118:0.011716:0.004738:0.004194:0.009168:0.010434:0.011716:0.011203:0.008210:0.011682:0.010434:0.004738:0.004738
(Malahyde Information Systems published :@0.131877:0.851095:0.480469:0.851095:0.480469:0.837090:0.131877:0.837090:0.006312:0.015719:0.011682:0.003421:0.011682:0.010434:0.009168:0.011716:0.011118:0.004379:0.003866:0.010434:0.005371:0.011203:0.005615:0.016044:0.011682:0.005798:0.003421:0.011203:0.010434:0.004379:0.008518:0.009168:0.006636:0.005798:0.011118:0.016044:0.006636:0.004379:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738
online, 1975).:@0.131877:0.865230:0.240336:0.865230:0.240336:0.851225:0.131877:0.851225:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
16. :@0.084840:0.879364:0.113267:0.879364:0.113267:0.865359:0.084840:0.865359:0.009476:0.009476:0.004738:0.004738
  GlaxoSmithKline.  ALKERAN . 1-8. (Pub-:@0.131877:0.879364:0.475747:0.879374:0.475747:0.865369:0.131877:0.865359:0.004738:-0.004738:0.014915:0.003421:0.011682:0.008210:0.011203:0.008518:0.016044:0.003421:0.005798:0.010434:0.010109:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.010504:0.012657:0.007902:0.010109:0.009168:0.010382:0.012657:0.012657:0.007443:0.004738:0.015240:0.009476:0.005679:0.009476:0.004738:0.015240:0.006312:0.010126:0.010399:0.011665:-0.274241
®:@0.359530:0.874380:0.366979:0.874380:0.366979:0.866214:0.359530:0.866214:0.007449
lished online 2003).:@0.131881:0.893509:0.287086:0.893509:0.287086:0.879503:0.131881:0.879503:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
17. :@0.084844:0.907643:0.113271:0.907643:0.113271:0.893638:0.084844:0.893638:0.009479:0.009479:0.004731:0.004738
 Gensia Sicor Pharmaceuticals, I. Thiotepa. :@0.131876:0.907643:0.480478:0.907643:0.480478:0.893638:0.131876:0.893638:0.000000:0.014385:0.010588:0.009903:0.006106:0.002891:0.011152:0.008757:0.007988:0.002891:0.010536:0.010673:0.004618:0.008757:0.009596:0.009903:0.011152:0.005092:0.015514:0.011152:0.010536:0.010588:0.009869:0.005268:0.002891:0.010536:0.011152:0.002891:0.006106:0.004208:0.008757:0.003335:0.004208:0.008757:0.006756:0.009903:0.002891:0.010673:0.005268:0.010588:0.011135:0.011152:0.004736:0.004738
1-2. (Cancer consultants, published online :@0.131881:0.921778:0.480500:0.921778:0.480500:0.907773:0.131881:0.907773:0.008946:0.005148:0.008946:0.004208:0.008928:0.005781:0.013376:0.011152:0.009903:0.010536:0.010588:0.004618:0.008928:0.010536:0.010673:0.009903:0.006106:0.009869:0.002891:0.005268:0.011152:0.009903:0.005268:0.006106:0.004208:0.008928:0.011135:0.009869:0.011135:0.002891:0.002891:0.006106:0.009903:0.010588:0.011186:0.008928:0.010673:0.009903:0.002891:0.002891:0.009903:0.011116:0.004738
2000).:@0.131881:0.935913:0.178182:0.935913:0.178182:0.921907:0.131881:0.921907:0.008946:0.008946:0.008946:0.008946:0.005781:0.004738
18. :@0.524238:0.078063:0.552665:0.078063:0.552665:0.064058:0.524238:0.064058:0.009476:0.009476:0.004738:0.004738
  Mitomycin.  8 February  2013 ed.  (Drug-:@0.571275:0.078063:0.915154:0.078063:0.915154:0.064058:0.571275:0.064058:0.004738:-0.004738:0.015719:0.003421:0.005798:0.011203:0.016044:0.009168:0.011067:0.003421:0.010434:0.004738:0.004738:0.005959:0.009476:0.010707:0.008296:0.011118:0.011665:0.005148:0.010399:0.011682:0.005148:0.009168:0.004738:0.005956:0.009476:0.009476:0.009488:0.009476:0.010707:0.011118:0.011716:0.004738:0.004738:0.005961:0.006312:0.012726:0.005148:0.010399:0.011511:0.005679
Bank, published online, 2013).:@0.571275:0.092362:0.814943:0.092362:0.814943:0.078357:0.571275:0.078357:0.009818:0.011682:0.010434:0.008586:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
19. :@0.524238:0.106661:0.552049:0.106661:0.552049:0.092656:0.524238:0.092656:0.009271:0.009271:0.004533:0.004738
 MGI PHARMA, I. Hexalen (altretamine)  :@0.571271:0.106661:0.919896:0.106661:0.919896:0.092656:0.571271:0.092656:0.000000:0.015514:0.014710:0.003660:0.013324:0.009921:0.011477:0.012452:0.010177:0.015514:0.012452:0.004533:0.013324:0.003660:0.004533:0.013324:0.011477:0.010913:0.008005:0.011477:0.003216:0.010913:0.010228:0.013324:0.006106:0.011477:0.003216:0.005593:0.004871:0.010913:0.005593:0.011477:0.015839:0.003216:0.010228:0.010913:0.006315:0.000000:0.004738
capsules (DailyMed, published online, :@0.571275:0.120961:0.919877:0.120961:0.919877:0.106955:0.571275:0.106955:0.010861:0.011477:0.011460:0.006431:0.010194:0.003216:0.010913:0.006431:0.017583:0.006106:0.012520:0.011477:0.003216:0.003216:0.008963:0.015514:0.010913:0.011511:0.004533:0.017583:0.011460:0.010194:0.011460:0.003216:0.003216:0.006431:0.010228:0.010913:0.011511:0.017583:0.010998:0.010228:0.003216:0.003216:0.010228:0.010913:0.004736:0.004738
2003).:@0.571275:0.135260:0.619201:0.135260:0.619201:0.121255:0.571275:0.121255:0.009271:0.009271:0.009271:0.009271:0.006106:0.004738
20. :@0.524238:0.149559:0.552665:0.149559:0.552665:0.135554:0.524238:0.135554:0.009476:0.009476:0.004738:0.004738
  Intramed  (Pty)  Ltd.  Mitomycin-c  2 mg :@0.571275:0.149559:0.919891:0.149559:0.919891:0.135554:0.571275:0.135554:0.004738:-0.004738:0.003866:0.010434:0.005798:0.005148:0.011682:0.016044:0.011118:0.011716:0.004738:0.007286:0.006312:0.010126:0.005798:0.009168:0.006312:0.004738:0.007292:0.007902:0.005798:0.011716:0.004738:0.004738:0.007288:0.015719:0.003421:0.005798:0.011203:0.016044:0.009168:0.011067:0.003421:0.010434:0.005679:0.011067:0.004738:0.007292:0.009476:0.012041:0.016044:0.011511:0.004738
powder  for  injection.  (Published online, :@0.571275:0.163859:0.919889:0.163859:0.919889:0.149853:0.571275:0.149853:0.011665:0.011203:0.014214:0.011716:0.011118:0.005148:0.004738:0.005752:0.005371:0.011203:0.005148:0.004738:0.005749:0.003421:0.010434:0.003472:0.011118:0.011067:0.005798:0.003421:0.011203:0.010434:0.004738:0.004738:0.005750:0.006312:0.010126:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.010502:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738
1985).:@0.571275:0.178158:0.620227:0.178158:0.620227:0.164152:0.571275:0.164152:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
21. :@0.524238:0.192457:0.552049:0.192457:0.552049:0.178452:0.524238:0.178452:0.009271:0.009271:0.004533:0.004738
 Morales-Ramírez P, Miranda-Pasaye S, :@0.571271:0.192457:0.919904:0.192457:0.919904:0.178452:0.571271:0.178452:0.000000:0.015514:0.010998:0.004943:0.011477:0.003216:0.010913:0.006431:0.005473:0.010177:0.011477:0.015839:0.003216:0.004871:0.010913:0.007064:0.017652:0.007813:0.004533:0.017652:0.015514:0.003216:0.004943:0.011477:0.010228:0.011511:0.011477:0.005473:0.009921:0.011477:0.006431:0.011477:0.008963:0.010913:0.017652:0.008313:0.004736:0.004738
Cruz-Vallejo VL, :@0.571275:0.206756:0.700739:0.206756:0.700739:0.192751:0.571275:0.192751:0.013701:0.004943:0.010194:0.007064:0.005473:0.010025:0.011477:0.003216:0.003216:0.010913:0.003267:0.010998:0.006209:0.011802:0.007697:0.004533:0.004738
et al:@0.702210:0.206756:0.739823:0.206756:0.739823:0.192751:0.702210:0.192751:0.010913:0.005593:0.006209:0.011477:0.003421
. Kinetic of genotoxic :@0.739618:0.206756:0.919932:0.206756:0.919932:0.192751:0.739618:0.192751:0.004533:0.006209:0.009903:0.003216:0.010228:0.010913:0.005593:0.003216:0.010861:0.006209:0.010998:0.005166:0.006209:0.011306:0.010913:0.010228:0.010998:0.005593:0.010998:0.008005:0.003216:0.011067:0.004738
expression in the pharmacodynamics of :@0.571275:0.221056:0.919868:0.221056:0.919868:0.207050:0.571275:0.207050:0.010913:0.008005:0.011460:0.004871:0.010913:0.006431:0.006431:0.003216:0.010998:0.010228:0.009390:0.003216:0.010228:0.009390:0.005593:0.010228:0.010913:0.009390:0.011460:0.010228:0.011477:0.005415:0.015839:0.011477:0.010861:0.010998:0.011511:0.008963:0.010228:0.011477:0.015839:0.003216:0.010861:0.006431:0.009390:0.010998:0.005371:0.004738
busulfan. :@0.571275:0.235355:0.648911:0.235355:0.648911:0.221350:0.571275:0.221350:0.011460:0.010194:0.006431:0.010194:0.003216:0.005166:0.011477:0.010228:0.004533:0.004738
Archives of Medical Research.:@0.653957:0.235355:0.915175:0.235355:0.915175:0.221350:0.653957:0.221350:0.012452:0.004943:0.010861:0.010228:0.003216:0.009271:0.010913:0.006431:0.009784:0.010998:0.005166:0.009784:0.015514:0.010913:0.011511:0.003216:0.010861:0.011477:0.003216:0.009784:0.010177:0.010913:0.006431:0.010913:0.011477:0.004943:0.010861:0.010228:0.004738
 :@0.915158:0.235355:0.919896:0.235355:0.919896:0.221350:0.915158:0.221350:0.004738
2006;37:316-321.:@0.571292:0.249654:0.701815:0.249654:0.701815:0.235649:0.571292:0.235649:0.009271:0.009271:0.009271:0.009271:0.004533:0.009271:0.009271:0.004533:0.009271:0.009271:0.009271:0.005473:0.009271:0.009271:0.009271:0.004738
22. :@0.524255:0.263953:0.552682:0.263953:0.552682:0.249948:0.524255:0.249948:0.009476:0.009476:0.004738:0.004738
  GlaxoSmithKline. Myleran. 1-11. (patient.:@0.571292:0.263953:0.915175:0.263953:0.915175:0.249948:0.571292:0.249948:0.004738:-0.004738:0.014915:0.003421:0.011682:0.008210:0.011203:0.008518:0.016044:0.003421:0.005798:0.010434:0.010109:0.003421:0.003421:0.010434:0.011118:0.004738:0.008586:0.015719:0.009168:0.003421:0.011118:0.005148:0.011682:0.010434:0.004738:0.008586:0.009476:0.005679:0.009476:0.009476:0.004738:0.008586:0.006312:0.011665:0.011682:0.005798:0.003421:0.011118:0.010434:0.005798:0.004738
cancerconsultants.com,  published  on-:@0.571292:0.278253:0.915168:0.278253:0.915168:0.264247:0.571292:0.264247:0.011067:0.011682:0.010434:0.011067:0.011118:0.005025:0.011067:0.011203:0.010434:0.006636:0.010399:0.003421:0.005798:0.011682:0.010434:0.005798:0.006636:0.004738:0.011067:0.011203:0.016044:0.004738:0.004738:0.012447:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010446:0.011118:0.011716:0.004738:0.012459:0.011203:0.010434:0.005679
line, 2004).:@0.571292:0.292552:0.658114:0.292552:0.658114:0.278547:0.571292:0.278547:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
23. :@0.524255:0.306851:0.552067:0.306851:0.552067:0.292846:0.524255:0.292846:0.009271:0.009271:0.004533:0.004738
 Merck Sharp & Dohme Corp. Temodar. :@0.571288:0.306851:0.919901:0.306851:0.919901:0.292846:0.571288:0.292846:0.000000:0.015514:0.010913:0.004823:0.010861:0.008381:0.010536:0.008313:0.010228:0.011477:0.004943:0.011460:0.010536:0.012743:0.010536:0.012520:0.010998:0.010228:0.015839:0.010913:0.010536:0.013701:0.010998:0.004943:0.011460:0.004533:0.010536:0.006241:0.010913:0.015839:0.010998:0.011511:0.011477:0.003688:0.004734:0.004738
1-14. (Merck & Co., Inc, published online, :@0.571292:0.321150:0.919903:0.321150:0.919903:0.307145:0.571292:0.307145:0.009271:0.005473:0.009271:0.009271:0.004533:0.006919:0.006106:0.015514:0.010913:0.004823:0.010861:0.008381:0.006917:0.012743:0.006917:0.013701:0.010998:0.004533:0.004533:0.006917:0.003660:0.010228:0.010861:0.004533:0.006917:0.011460:0.010194:0.011460:0.003216:0.003216:0.006431:0.010228:0.010913:0.011511:0.006917:0.010998:0.010228:0.003216:0.003216:0.010228:0.010913:0.004736:0.004738
1999).:@0.571292:0.335450:0.619218:0.335450:0.619218:0.321444:0.571292:0.321444:0.009271:0.009271:0.009271:0.009271:0.006106:0.004738
24. :@0.524255:0.349749:0.552682:0.349749:0.552682:0.335744:0.524255:0.335744:0.009476:0.009476:0.004738:0.004738
  Decatris  MP,  Sundar  S,  O’Byrne  KJ.  Plati-:@0.571292:0.349749:0.915151:0.349749:0.915151:0.335744:0.571292:0.335744:0.004738:-0.004738:0.012726:0.011118:0.011067:0.011682:0.005798:0.005148:0.003421:0.006636:0.004738:0.003019:0.015719:0.008017:0.004738:0.004738:0.003014:0.008518:0.010399:0.010434:0.011716:0.011682:0.005148:0.004738:0.003012:0.008518:0.004738:0.004738:0.003014:0.014864:0.006004:0.009818:0.009168:0.005506:0.010434:0.011118:0.004738:0.003012:0.010109:0.008244:0.004738:0.004738:0.003009:0.010126:0.003421:0.011682:0.005798:0.003421:0.005679
num-based chemotherapy in metastatic :@0.571292:0.364048:0.919899:0.364048:0.919899:0.350043:0.571292:0.350043:0.010434:0.010399:0.016044:0.005679:0.011665:0.011682:0.006636:0.011118:0.011716:0.006910:0.011067:0.010434:0.011118:0.016044:0.011203:0.005798:0.010434:0.011118:0.005148:0.011682:0.011665:0.009168:0.006896:0.003421:0.010434:0.006910:0.016044:0.011118:0.005798:0.011682:0.006636:0.005798:0.011682:0.005798:0.003421:0.011067:0.004738
breast cancer:  current  status. :@0.571292:0.378347:0.843417:0.378347:0.843417:0.364342:0.571292:0.364342:0.011665:0.005080:0.011118:0.011682:0.006636:0.005798:0.013153:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738:0.004738:0.008398:0.011067:0.010399:0.005148:0.005073:0.011118:0.010434:0.005798:0.004738:0.008400:0.006636:0.005798:0.011682:0.005798:0.010399:0.006636:0.004738:0.004738
Cancer :@0.851820:0.378347:0.919913:0.378347:0.919913:0.364342:0.851820:0.364342:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004738
Treatment Reviews.:@0.571292:0.392647:0.731560:0.392647:0.731560:0.378641:0.571292:0.378641:0.007286:0.005148:0.011118:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.006636:0.004738
 2004;30 53-81.:@0.731543:0.392647:0.850999:0.392647:0.850999:0.378641:0.731543:0.378641:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004806:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
::@0.797890:0.392647:0.802680:0.392647:0.802680:0.378394:0.797890:0.378394:0.004789
25. :@0.524255:0.406946:0.552682:0.406946:0.552682:0.392941:0.524255:0.392941:0.009479:0.009479:0.004731:0.004738
 Nussbaumer S, Bonnabry P, Veuthey JL, :@0.571288:0.406946:0.897144:0.406946:0.897144:0.392941:0.571288:0.392941:0.000000:0.012452:0.010194:0.006431:0.006431:0.011460:0.011477:0.010194:0.015839:0.010913:0.004943:0.006106:0.008313:0.004533:0.006106:0.009613:0.010998:0.010228:0.010228:0.011477:0.011460:0.004943:0.008963:0.006106:0.007812:0.004533:0.006106:0.010076:0.010913:0.010194:0.005593:0.010228:0.010913:0.008963:0.006106:0.008039:0.007697:0.004533:0.004738
et :@0.898512:0.406946:0.919959:0.406946:0.919959:0.392941:0.898512:0.392941:0.010913:0.005797:0.004738
al:@0.571292:0.421245:0.586190:0.421245:0.586190:0.407240:0.571292:0.407240:0.011477:0.003421
. Analysis of anticancer drugs: a review. :@0.585984:0.421245:0.919927:0.421245:0.919927:0.407240:0.585984:0.407240:0.004533:0.006329:0.012452:0.010228:0.011477:0.003216:0.008963:0.006431:0.003216:0.006431:0.006329:0.010998:0.005166:0.006329:0.011477:0.010228:0.005593:0.003216:0.010861:0.011477:0.010228:0.010861:0.010913:0.004943:0.006329:0.011511:0.004943:0.010194:0.011306:0.006431:0.004533:0.006329:0.011477:0.006329:0.004873:0.010913:0.009271:0.003216:0.010913:0.014008:0.004736:0.004738
Talanta.:@0.571292:0.435544:0.636579:0.435544:0.636579:0.421539:0.571292:0.421539:0.007081:0.011477:0.003216:0.011477:0.010228:0.005593:0.011477:0.004738
 2011;85:2265-2289.:@0.636374:0.435544:0.789971:0.435544:0.789971:0.421539:0.636374:0.421539:0.004533:0.009271:0.009271:0.009271:0.009271:0.004533:0.009271:0.009271:0.004533:0.009271:0.009271:0.009271:0.009271:0.005473:0.009271:0.009271:0.009271:0.009271:0.004738
26. :@0.524255:0.449844:0.551759:0.449844:0.551759:0.435838:0.524255:0.435838:0.009168:0.009168:0.004430:0.004738
 Trigg ME, Flanigan-Minnick A. Mechanisms :@0.571287:0.449844:0.919916:0.449844:0.919916:0.435838:0.571287:0.435838:0.000000:0.006465:0.004841:0.003113:0.011203:0.011203:0.006611:0.015411:0.008860:0.004430:0.006611:0.007988:0.003113:0.011374:0.010126:0.003113:0.011203:0.011374:0.010126:0.005371:0.015411:0.003113:0.010126:0.010126:0.003113:0.010759:0.008279:0.006611:0.012349:0.004430:0.006611:0.015411:0.010810:0.010759:0.010126:0.011374:0.010126:0.003113:0.006329:0.015736:0.006640:0.004738
of action of commonly used drugs to treat :@0.571292:0.464143:0.919957:0.464143:0.919957:0.450138:0.571292:0.450138:0.010895:0.005063:0.005285:0.011374:0.010759:0.005490:0.003113:0.010895:0.010126:0.005285:0.010895:0.005063:0.005285:0.010759:0.010895:0.015736:0.015736:0.010895:0.010126:0.003113:0.008860:0.005285:0.010092:0.006329:0.010810:0.011409:0.005285:0.011409:0.004841:0.010092:0.011203:0.006329:0.005285:0.005490:0.010895:0.005285:0.005490:0.004769:0.010810:0.011374:0.005795:0.004738
cancer. :@0.571292:0.478442:0.637872:0.478442:0.637872:0.464437:0.571292:0.464437:0.010759:0.011374:0.010126:0.010759:0.010810:0.003585:0.004430:0.004738
Community Oncology.:@0.649305:0.478442:0.844277:0.478442:0.844277:0.464437:0.649305:0.464437:0.013598:0.010895:0.015736:0.015736:0.010092:0.010126:0.003113:0.005490:0.008860:0.016181:0.014556:0.010126:0.010759:0.010895:0.003113:0.010895:0.011203:0.008860:0.004738
 2011;8: :@0.843970:0.478442:0.919892:0.478442:0.919892:0.464437:0.843970:0.464437:0.016181:0.009168:0.009168:0.009168:0.009168:0.004430:0.009168:0.004734:0.004738
357-369.:@0.571292:0.492741:0.636408:0.492741:0.636408:0.478736:0.571292:0.478736:0.009168:0.009168:0.009168:0.005371:0.009168:0.009168:0.009168:0.004738
27. :@0.524255:0.507041:0.552682:0.507041:0.552682:0.493035:0.524255:0.493035:0.009479:0.009479:0.004731:0.004738
 Solomon EP, Berg LR, Martin DW. :@0.571287:0.507041:0.849036:0.507041:0.849036:0.493035:0.571287:0.493035:0.000000:0.008347:0.011032:0.003250:0.011032:0.015873:0.011032:0.010263:0.007611:0.008997:0.007846:0.004567:0.007611:0.009647:0.010947:0.004989:0.011340:0.007611:0.007731:0.010211:0.004567:0.007611:0.015548:0.011511:0.004977:0.005627:0.003250:0.010263:0.007611:0.012555:0.014980:0.004567:0.004738
Biology:@0.851909:0.507041:0.910629:0.507041:0.910629:0.493035:0.851909:0.493035:0.009647:0.003250:0.011032:0.003250:0.011032:0.011340:0.009168
. :@0.910458:0.507041:0.919933:0.507041:0.919933:0.493035:0.910458:0.493035:0.004738:0.004738
2002 pg 1254. Brooks/Cole Publishing, USA.:@0.571292:0.521340:0.914660:0.521340:0.914660:0.507335:0.571292:0.507335:0.009305:0.009305:0.009305:0.009305:0.004567:0.011494:0.011340:0.004567:0.009305:0.009305:0.009305:0.009305:0.004567:0.004567:0.009647:0.004907:0.011032:0.011032:0.008415:0.006465:0.007304:0.013735:0.011032:0.003250:0.010947:0.004567:0.009955:0.010228:0.011494:0.003250:0.003250:0.006465:0.010263:0.003250:0.010263:0.011340:0.004567:0.004567:0.011032:0.008347:0.012486:0.004738
28. :@0.524255:0.535639:0.552682:0.535639:0.552682:0.521634:0.524255:0.521634:0.009476:0.009476:0.004738:0.004738
  Fairbanks DJ, Andersen WR.:@0.571292:0.535639:0.799286:0.535639:0.799286:0.521634:0.571292:0.521634:0.004738:-0.004738:0.008296:0.011682:0.003421:0.005148:0.011665:0.011682:0.010434:0.008586:0.006636:0.004652:0.012726:0.008244:0.004738:0.004644:0.012657:0.010434:0.011716:0.011118:0.005148:0.006636:0.011118:0.010434:0.004637:0.016420:0.010382:0.004738
 Genetics: the :@0.799286:0.535639:0.919915:0.535639:0.919915:0.521634:0.799286:0.521634:0.004652:0.014915:0.011118:0.010434:0.011118:0.005798:0.003421:0.011067:0.006636:0.004738:0.004644:0.005798:0.010434:0.011118:0.004738
Continuity of Life.:@0.571292:0.549938:0.720989:0.549938:0.720989:0.535933:0.571292:0.535933:0.013906:0.011203:0.010434:0.005798:0.003421:0.010434:0.010399:0.003421:0.005798:0.009168:0.008296:0.011203:0.005371:0.008296:0.007902:0.003421:0.005371:0.011118:0.004738
 Chicago: Brooks/Cole :@0.720989:0.549938:0.919923:0.549938:0.919923:0.535933:0.720989:0.535933:0.008296:0.013906:0.010434:0.003421:0.011067:0.011682:0.011511:0.011203:0.004738:0.008296:0.009818:0.005082:0.011203:0.011195:0.008586:0.006636:0.007475:0.013906:0.011203:0.003421:0.011118:0.004738
Publishing USA. 1999;pg 820.:@0.571292:0.564238:0.803073:0.564238:0.803073:0.550232:0.571292:0.550232:0.010126:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.003421:0.010434:0.011511:0.004738:0.011203:0.008518:0.012657:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.011665:0.011511:0.004738:0.009476:0.009476:0.009476:0.004738
29. :@0.524255:0.578537:0.552682:0.578537:0.552682:0.564532:0.524255:0.564532:0.009476:0.009476:0.004738:0.004738
  Azacitidine.  8 February  2013 Ed.  (Drug-:@0.571292:0.578537:0.915170:0.578537:0.915170:0.564532:0.571292:0.564532:0.004738:-0.004738:0.012657:0.007269:0.011682:0.011067:0.003421:0.005798:0.003421:0.011716:0.003421:0.010434:0.011118:0.004738:0.004738:0.005203:0.009476:0.009955:0.008296:0.011118:0.011665:0.005148:0.010399:0.011682:0.005148:0.009168:0.004738:0.005200:0.009476:0.009476:0.009476:0.009476:0.009955:0.009168:0.011716:0.004738:0.004738:0.005208:0.006312:0.012726:0.005148:0.010399:0.011511:0.005679
Bank, published online, 2013).:@0.571292:0.592836:0.814961:0.592836:0.814961:0.578831:0.571292:0.578831:0.009818:0.011682:0.010434:0.008586:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
30. :@0.524255:0.607136:0.552682:0.607136:0.552682:0.593130:0.524255:0.593130:0.009476:0.009476:0.004738:0.004738
  Celgene Corporation. (Vidaza) Highlights :@0.571292:0.607136:0.919903:0.607136:0.919903:0.593130:0.571292:0.593130:0.004738:-0.004738:0.013906:0.011118:0.003421:0.011511:0.011118:0.010434:0.011118:0.005643:0.013906:0.011203:0.005148:0.011665:0.011203:0.005148:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.005632:0.006312:0.012096:0.003421:0.011716:0.011682:0.007269:0.011682:0.006312:0.005662:0.011682:0.003421:0.011511:0.010434:0.003421:0.003421:0.011511:0.010434:0.005798:0.006636:0.004738
of  prescribing  information.  Vol.  VIDPI.006 :@0.571292:0.621435:0.919886:0.621435:0.919886:0.607429:0.571292:0.607429:0.011203:0.005371:0.004738:0.003099:0.011665:0.005078:0.011118:0.006636:0.011067:0.005148:0.003421:0.011665:0.003421:0.010434:0.011511:0.004738:0.003104:0.003421:0.010434:0.005371:0.011203:0.005617:0.016044:0.011682:0.005798:0.003421:0.011203:0.010434:0.004738:0.004738:0.003096:0.010281:0.011203:0.003421:0.004738:0.004738:0.003101:0.012007:0.003866:0.012726:0.010126:0.003866:0.004738:0.009476:0.009476:0.009476:0.004738
01/12 1-7. (Published online, 2004).:@0.571292:0.635734:0.853958:0.635734:0.853958:0.621729:0.571292:0.621729:0.009476:0.009476:0.007475:0.009476:0.009476:0.004738:0.009476:0.005679:0.009476:0.004738:0.004738:0.006312:0.010126:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
31. :@0.524255:0.650033:0.552682:0.650033:0.552682:0.636028:0.524255:0.636028:0.009476:0.009476:0.004738:0.004738
  Bristol Myers Squibb  Company. Hydrea :@0.571292:0.650033:0.919892:0.650033:0.919892:0.636028:0.571292:0.636028:0.004738:-0.004738:0.009818:0.005148:0.003421:0.006636:0.005798:0.011203:0.003421:0.010998:0.015719:0.009168:0.011118:0.005148:0.006636:0.010998:0.008518:0.011665:0.010399:0.003421:0.011665:0.011665:0.004738:0.006272:0.013906:0.011203:0.016044:0.011665:0.011682:0.010434:0.009168:0.004738:0.010998:0.011682:0.009168:0.011716:0.005082:0.011118:0.011682:0.004738
capsules. (South African electronic pack-:@0.571292:0.664333:0.915165:0.664333:0.915165:0.650327:0.571292:0.650327:0.011067:0.011682:0.011665:0.006636:0.010399:0.003421:0.011118:0.006636:0.004738:0.005422:0.006312:0.008518:0.011203:0.010399:0.005798:0.010434:0.005410:0.012657:0.005371:0.005148:0.003421:0.011067:0.011682:0.010434:0.005412:0.011118:0.003421:0.011118:0.011067:0.005798:0.005075:0.011203:0.010434:0.003421:0.011067:0.005422:0.011665:0.011682:0.011067:0.008586:0.005679
age insert, published online, 2005).:@0.571292:0.678632:0.856045:0.678632:0.856045:0.664627:0.571292:0.664627:0.011682:0.011511:0.011118:0.004738:0.003421:0.010434:0.006636:0.011118:0.005148:0.005798:0.004738:0.004738:0.011665:0.010399:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011203:0.010434:0.003421:0.003421:0.010434:0.011118:0.004738:0.004738:0.009476:0.009476:0.009476:0.009476:0.006312:0.004738
32. :@0.524255:0.692931:0.552682:0.692931:0.552682:0.678926:0.524255:0.678926:0.009476:0.009476:0.004738:0.004738
  Joel S. The clinical  pharmacology of :@0.571292:0.692931:0.919921:0.692931:0.919921:0.678926:0.571292:0.678926:0.004738:-0.004738:0.008244:0.011203:0.011118:0.003421:0.013718:0.008518:0.004738:0.013718:0.007286:0.010434:0.011118:0.013718:0.011067:0.003421:0.003421:0.010434:0.003421:0.011067:0.011682:0.003421:0.004738:0.008993:0.011665:0.010434:0.011682:0.005622:0.016044:0.011682:0.011067:0.011203:0.003421:0.011203:0.011511:0.009168:0.013718:0.011203:0.005371:0.004738
etoposide: an update. :@0.571292:0.707230:0.763015:0.707230:0.763015:0.693225:0.571292:0.693225:0.011118:0.005798:0.011203:0.011665:0.011203:0.006636:0.003421:0.011716:0.011118:0.004738:0.004567:0.011682:0.010434:0.004567:0.010399:0.011665:0.011716:0.011682:0.005798:0.011118:0.004738:0.004738
Cancer Treatment :@0.762844:0.707230:0.919921:0.707230:0.919921:0.693225:0.762844:0.693225:0.013906:0.011682:0.010434:0.011067:0.011118:0.005148:0.004567:0.007286:0.005148:0.011109:0.011682:0.005798:0.016044:0.011118:0.010434:0.005798:0.004738
Reviews.:@0.571292:0.721530:0.642395:0.721530:0.642395:0.707524:0.571292:0.707524:0.010382:0.011118:0.009476:0.003421:0.011118:0.014214:0.006636:0.004738
 1996;22:79-221.:@0.642395:0.721530:0.771259:0.721530:0.771259:0.707524:0.642395:0.707524:0.004738:0.009476:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.009476:0.004738
33. :@0.524255:0.735829:0.552682:0.735829:0.552682:0.721824:0.524255:0.721824:0.009476:0.009476:0.004738:0.004738
  Kontek  R, Matlawska-Wasowska K, Ka-:@0.571292:0.735829:0.915172:0.735829:0.915172:0.721824:0.571292:0.721824:0.004738:-0.004738:0.010109:0.011203:0.010434:0.005798:0.011118:0.008586:0.004738:0.007220:0.010382:0.004738:0.011973:0.015719:0.011682:0.005798:0.003421:0.011682:0.014214:0.006636:0.008586:0.011682:0.005679:0.015577:0.011682:0.006636:0.011203:0.014214:0.006636:0.008586:0.011682:0.011973:0.010109:0.004738:0.011973:0.010109:0.011682:0.005679
linowska-Lis U,:@0.571292:0.750128:0.686727:0.750128:0.686727:0.736123:0.571292:0.736123:0.003421:0.003421:0.010434:0.011203:0.014214:0.006636:0.008586:0.011682:0.005679:0.007902:0.003421:0.006636:0.006258:0.011203:0.004738
 et al.:@0.686727:0.750128:0.735971:0.750128:0.735971:0.736123:0.686727:0.736123:0.006243:0.011118:0.005798:0.006243:0.011682:0.003421:0.004738
 Genotoxic effects of :@0.735971:0.750128:0.919909:0.750128:0.919909:0.736123:0.735971:0.736123:0.006243:0.014915:0.011118:0.010434:0.011203:0.005798:0.011203:0.008210:0.003421:0.011067:0.006243:0.011118:0.005420:0.005371:0.011118:0.011067:0.005798:0.006636:0.006243:0.011203:0.005371:0.004738
irinotecan combined with the novel plati-:@0.571292:0.764427:0.915170:0.764427:0.915170:0.750422:0.571292:0.750422:0.003421:0.005148:0.003421:0.010434:0.011203:0.005798:0.011118:0.011067:0.011682:0.010434:0.004983:0.011067:0.011203:0.016044:0.011665:0.003421:0.010434:0.011118:0.011716:0.004994:0.014214:0.003421:0.005798:0.010434:0.004994:0.005798:0.010434:0.011118:0.004984:0.010434:0.011203:0.009476:0.011118:0.003421:0.004994:0.011665:0.003421:0.011682:0.005798:0.003421:0.005679
num (II) complexes in human cancer cells. :@0.571292:0.778727:0.919898:0.778727:0.919898:0.764721:0.571292:0.764721:0.010434:0.010399:0.016044:0.003900:0.006312:0.003866:0.003866:0.006312:0.003910:0.011067:0.011203:0.016044:0.011665:0.003421:0.011118:0.008210:0.011118:0.006636:0.003900:0.003421:0.010434:0.003900:0.010434:0.010399:0.016044:0.011682:0.010434:0.003900:0.011067:0.011682:0.010434:0.011067:0.011118:0.005148:0.003900:0.010861:0.010911:0.003219:0.003219:0.006435:0.004738:0.004738
Chemico-Biological:@0.571292:0.793026:0.730636:0.793026:0.730636:0.779021:0.571292:0.779021:0.013701:0.010228:0.010913:0.015839:0.003216:0.010861:0.010998:0.005473:0.009613:0.003216:0.010998:0.003216:0.010998:0.011306:0.003216:0.010861:0.011477:0.003216
Interactions:@0.816295:0.793026:0.910642:0.793026:0.910642:0.779021:0.816295:0.779021:0.003660:0.010228:0.005593:0.010913:0.004943:0.011477:0.010861:0.005593:0.003216:0.010998:0.010228:0.006636
. :@0.910437:0.793026:0.919913:0.793026:0.919913:0.779021:0.910437:0.779021:0.004738:0.004738
2010;188:66-74.:@0.571292:0.807325:0.694412:0.807325:0.694412:0.793320:0.571292:0.793320:0.009274:0.009274:0.009274:0.009274:0.004529:0.009476:0.009476:0.009486:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
34. :@0.524255:0.821624:0.552682:0.821624:0.552682:0.807619:0.524255:0.807619:0.009476:0.009476:0.004738:0.004738
  Kennedy S, DiCesare JC, Sheaff RJ. Topoi-:@0.571292:0.821624:0.915180:0.821624:0.915180:0.807619:0.571292:0.807619:0.004738:-0.004738:0.010109:0.011118:0.010434:0.010434:0.011118:0.011716:0.009168:0.004738:0.008518:0.004738:0.004738:0.012726:0.003421:0.013906:0.011118:0.006636:0.011682:0.005087:0.011118:0.004738:0.008244:0.013906:0.004738:0.004738:0.008518:0.010434:0.011118:0.011682:0.005420:0.005371:0.004738:0.010382:0.008244:0.004738:0.004738:0.006448:0.011203:0.011665:0.011203:0.003421:0.005679
somerase I/II inhibition by a novel naph-:@0.571292:0.835924:0.915175:0.835924:0.915175:0.821918:0.571292:0.821918:0.006636:0.011203:0.016044:0.011118:0.005148:0.011682:0.006636:0.011118:0.007252:0.003866:0.007475:0.003866:0.003866:0.007252:0.003421:0.010434:0.010434:0.003421:0.011665:0.003421:0.005798:0.003421:0.011203:0.010434:0.007252:0.011665:0.009168:0.007252:0.011682:0.007252:0.010434:0.011203:0.009476:0.011118:0.003421:0.007252:0.010434:0.011682:0.011665:0.010434:0.005679
thoquinone  containing  a  modified  an-:@0.571292:0.850223:0.915173:0.850223:0.915173:0.836218:0.571292:0.836218:0.005798:0.010434:0.011203:0.011665:0.010399:0.003421:0.010434:0.011203:0.010434:0.011118:0.004738:0.006587:0.011067:0.011203:0.010434:0.005798:0.011682:0.003421:0.010434:0.003421:0.010434:0.011511:0.004738:0.006601:0.011682:0.004738:0.006602:0.016044:0.011203:0.011716:0.003421:0.004165:0.004165:0.011118:0.011716:0.004738:0.006601:0.011682:0.010434:0.005679
thracycline ring system. :@0.571292:0.864522:0.771404:0.864522:0.771404:0.850517:0.571292:0.850517:0.005798:0.010434:0.005148:0.011682:0.011067:0.009168:0.011067:0.003421:0.003421:0.010434:0.011118:0.005987:0.005148:0.003421:0.010434:0.011511:0.005978:0.006636:0.009168:0.006636:0.005798:0.011118:0.016044:0.004738:0.004738
Biochemical and :@0.772653:0.864522:0.919904:0.864522:0.919904:0.850517:0.772653:0.850517:0.009818:0.003421:0.011203:0.011067:0.010434:0.011118:0.016044:0.003421:0.011067:0.011682:0.003421:0.005987:0.011682:0.010434:0.011716:0.004738
Biophysical  Research Communications.:@0.571292:0.878821:0.915168:0.878821:0.915168:0.864816:0.571292:0.864816:0.009818:0.003421:0.011203:0.011665:0.010434:0.009168:0.006636:0.003421:0.011067:0.011682:0.003421:0.004738:0.009238:0.010382:0.011118:0.006636:0.011118:0.011682:0.005148:0.011067:0.010434:0.013957:0.013906:0.011203:0.016044:0.016044:0.010399:0.010425:0.003421:0.011067:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738
 :@0.915168:0.878821:0.919906:0.878821:0.919906:0.864816:0.915168:0.864816:0.004738
2011; 408:94-98.:@0.571292:0.893121:0.700156:0.893121:0.700156:0.879115:0.571292:0.879115:0.009476:0.009476:0.009476:0.009476:0.004738:0.004738:0.009476:0.009476:0.009476:0.004738:0.009476:0.009476:0.005679:0.009476:0.009476:0.004738
35. :@0.524255:0.907420:0.552682:0.907420:0.552682:0.893415:0.524255:0.893415:0.009479:0.009479:0.004731:0.004738
  Tourani JM,:@0.571287:0.907420:0.663088:0.907420:0.663088:0.893415:0.571287:0.893415:0.004738:-0.004738:0.006243:0.010998:0.010194:0.004943:0.011477:0.010228:0.003216:0.006211:0.008039:0.015514:0.004738
 et al.:@0.662882:0.907420:0.711236:0.907420:0.711236:0.893415:0.662882:0.893415:0.006209:0.010913:0.005593:0.006209:0.011477:0.003216:0.004738
 Influence of age on the :@0.711031:0.907420:0.919933:0.907420:0.919933:0.893415:0.711031:0.893415:0.006211:0.003660:0.010228:0.004045:0.004045:0.010194:0.010913:0.010228:0.010861:0.010913:0.006211:0.010998:0.005166:0.006211:0.011477:0.011306:0.010913:0.006211:0.010998:0.010228:0.006211:0.005593:0.010228:0.011116:0.004738
pharmacokinetics  of  i.v.  vinflunine:  results :@0.571292:0.921719:0.919904:0.921719:0.919904:0.907714:0.571292:0.907714:0.011460:0.010228:0.011477:0.005415:0.015839:0.011477:0.010861:0.010998:0.008381:0.003216:0.010228:0.010913:0.005593:0.003216:0.010861:0.006431:0.004738:0.003159:0.010998:0.005166:0.004738:0.003159:0.003216:0.004533:0.009271:0.004533:0.004738:0.003159:0.009271:0.003216:0.010228:0.004045:0.004045:0.010194:0.010228:0.003216:0.010228:0.010913:0.004533:0.004738:0.003161:0.004871:0.010913:0.006431:0.010194:0.003216:0.005593:0.006640:0.004738
of a phase I trial in elderly cancer patients. :@0.571292:0.936018:0.919920:0.936018:0.919920:0.922013:0.571292:0.922013:0.010998:0.005166:0.004704:0.011477:0.004695:0.011460:0.010228:0.011477:0.006431:0.010913:0.004695:0.003660:0.004695:0.005593:0.004943:0.003216:0.011477:0.003216:0.004695:0.003216:0.010228:0.004695:0.010913:0.003216:0.011511:0.010913:0.004943:0.003216:0.008963:0.004704:0.010861:0.011477:0.010228:0.010861:0.010913:0.004943:0.004704:0.011460:0.011477:0.005593:0.003216:0.010913:0.010228:0.005593:0.006431:0.004736:0.004738
References:@0.786077:0.038601:0.914549:0.038601:0.914549:0.019343:0.786077:0.019343:0.014276:0.015287:0.007385:0.015287:0.006976:0.015287:0.014346:0.015216:0.015287:0.009125